Michael Sangi

USPTO Granted Patents = 22 (Patent Applications = 10)

CIPO Patents = 2

EPO Patents = 10 (Patent Applications = 7)

Average Co-Inventor Count = 7.8

ph-index = 6

Forward Citations = 85(Granted Patents)

Location History:

Oakland, CA (US) (2013 - 2016)
San Mateo, CA (US) (2016 - 2024)

Company Filing History:

18 out of 919

Gilead Sciences, Inc.

patents

2 out of 79

Gilead Pharmasset LLC

patents

1 out of 1

The Liver Company Inc.

Years Active: 2013-2025

Loading Chart...

22 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12240862 - Inhibitors of peptidylarginine deiminases (2025-03-04),

2. 12049439 - Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives (2024-07-30),

3. 11976083 - Inhibitors of peptidylarginine deiminases (2024-05-07),

4. 11878965 - Inhibitors of peptidylarginine deiminases (2024-01-23),

5. 11136290 - Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives (2021-10-05),

6. 10603318 - Inhibitors of hepatitis C virus (2020-03-31),

7. 10335409 - Inhibitors of hepatitis C virus (2019-07-02),

8. 10174038 - Compounds and methods for antiviral treatment (2019-01-08),

9. 10030033 - Synthesis of an antiviral compound (2018-07-24),

10. 10005774 - Syk inhibitors (2018-06-26),

11. 9957275 - Pyrazolo[1,5-A]pyrimidines for antiviral treatment (2018-05-01),

12. 9655944 - Inhibitors of hepatitis C virus (2017-05-23),

13. 9504689 - Compounds and methods for antiviral treatment (2016-11-29),

14. 9440991 - Synthesis of an antiviral compound (2016-09-13),

15. 9376441 - Substituted pyrrolidines as SYK inhibitors (2016-06-28),

Title: Michael Sangi: Innovator in Therapeutic Compounds

Introduction

Michael Sangi is a notable inventor based in San Mateo, California. With a robust portfolio of 21 patents, he has made significant contributions to the field of pharmaceutical science, particularly in the development of therapeutic compounds.

Latest Patents

Among his most recent innovations are the patents for sulfinylaminobenzamide and sulfonylaminobenzamide derivatives. These compounds, represented by a specific formula, serve as inhibitors of peptidylarginine deiminases (PADs). Notably, this includes advancements targeting peptidylarginine deiminase type 4 (PAD4). The patent covers not only the novel compounds but also the processes and intermediates for their preparation, methods of use, and pharmaceutical compositions that include these compounds, demonstrating their potential therapeutic applications.

Career Highlights

Michael has a distinguished career, having worked at Gilead Sciences, Inc. and Gilead Pharmasset LLC, where he contributed to pioneering research and development projects in the pharmaceutical sector. His academic background and invention portfolio underscore his role as a leading inventor in therapeutic innovation.

Collaborations

In his journey, Michael has collaborated with respected professionals like Dustin S. Siegel and Adam James Schrier. Their teamwork has been instrumental in driving forward the development of new therapeutic approaches and enhancing the impact of their research efforts.

Conclusion

Michael Sangi's contributions to the pharmaceutical industry reflect a commitment to innovation and therapeutic efficacy. His patents, particularly in the area of PAD inhibitors, highlight his role in advancing medical science and improving treatment options for various diseases. As an inventor, Michael continues to pave the way for future innovations in pharmaceutical compounds.

This text is generated by artificial intelligence and may not be accurate.